Thanh Lam Tran, MD
Vascular Neurology · Hackensack, NJNPI 1154818383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bristol Myers Squibb at 38.6% of the total. Reporting peaked in 2024 at $287 and has fallen 61.9% since, to $110 in 2025.
Across 25 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$178
- Lilly USA, LLC$73
- Teva Pharmaceuticals USA, Inc.$67
- Biogen$50
- Philips North America LLC$21
- Vanda Pharmaceuticals Inc.$19
- plus $54 from 3 others
What the payments were for
- Food & beverage$461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 10 | $178 |
| Lilly USA, LLC | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Biogen | 2 | $50 |
| Philips North America LLC | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| AbbVie | 1 | $18 |
How this compares
Too few vascular neurology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $15,547 |
| Ezetimibe | 12 | $520 |
| Cilostazol | 14 | $495 |
| Rosuvastatin Calcium | 17 | $260 |
| Atorvastatin Calcium | 16 | $175 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Hackensack
- Kevin CrutchfieldHackensack$19K
- Inder SinghNeptune$119K
- Fred RinconCamden$85K
- Peter BarcasNeptune$10K
- Kiwon LeeSummit$7K
- John HannaSummit$3K
- Pratit PatelNeptune$3K
- Laura RisleyNeptune$3K
- Gerald FerenczToms River$2K
- Steven ShapiroLivingston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.